Anavex Life Sciences Corp (AVXL)

[frrol]

Two likeliest explanations:

1. Some cannot tolerate higher doses and are on their MTD.
2. Consistent dosing from Part B through C helps with data analysis, though is not very adaptive.

It could be both reasons. And #1 is not inconsistent with Missling's statements about "non-optimized dosing", though he may mean it differently than the general understanding of the term. Optimal dosing may ultimately mean 2x daily. It's a stretch, yes. There are open questions around the trial. This is one of them.

Other questions: Why haven't P300 results beyond the 5 week mark (eg, 52 weeks) been released if it is a great cognitive biomarker? What happened with the previous two sub group trends? Why no more talk about muscarinic modulation? Why no 18 month results release? We should get Part C results at 104 weeks, so that can wait, though 6 month interval data is reasonable. The other stuff is just outright puzzling omissions. And no he's not trying to "burn the shorts". The data is just probably very cloudy. He's releasing what he's comfortable releasing.